STAT+: ‘Learning each other’s language’: FDA, patent office seek to work together to lower drug prices
STAT
DECEMBER 7, 2023
In 1997, Celgene obtained a key patent for what would become a blockbuster blood cancer treatment, giving it a monopoly until 2019. Not long after the patent was awarded, the company leveraged federally funded research and began investigating different forms of the compound, called Revlimid.
Let's personalize your content